Compare FMBH & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMBH | NVAX |
|---|---|---|
| Founded | 1865 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1995 | 1996 |
| Metric | FMBH | NVAX |
|---|---|---|
| Price | $48.83 | $8.39 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $43.40 | $11.33 |
| AVG Volume (30 Days) | 169.8K | ★ 4.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | 16.06 | ★ 309.76 |
| EPS | ★ 1.06 | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | $45.28 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $34.51 | $6.20 |
| 52 Week High | $49.64 | $11.85 |
| Indicator | FMBH | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 38.42 |
| Support Level | $47.02 | $7.96 |
| Resistance Level | $49.34 | $10.10 |
| Average True Range (ATR) | 1.10 | 0.48 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 73.85 | 9.16 |
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.